Maria Luisa Pineda ^UDM

Dr. Maria Luisa Pineda, co-founder of Envisagenics, plays a key role in harnessing RNA splicing analytics and AI for therapeutic solutions. Her work focuses on RNA therapeutics discovery for genetic diseases and cancer, driven by the company's innovative SpliceCore platform. This platform, through AI, enables efficient drug target prediction and biomarker discovery from RNA-seq data, marking a significant advancement in reducing drug development costs and time.